Catherine Kolonko

Patients with hepatitis C genotype 3 may face more liver problems.

Hepatitis C reinfection rates appear to be higher within certain populations.

Glecaprevir/pibrentasvir had a 99% SVR rate in a Japanese population.

The Penn Medicine clinical trial uses kidneys from deceased donors who were infected with the hepatitis C virus. The first person in the trial received a kidney transplant in July and then underwent treatment with a regimen of Zepatier, one of the direct acting antiviral drugs approved recently to treat the virus.

The US Department of Veteran Affairs is finding success with modern DAAs.

Even after eradicating hepatitis C with direct-acting antivirals, high frequency of Tregs could pose complications.

Merck just got $2.54 billion richer with the ruling of a federal jury.

An investigational regimen of glecaprevir and pibrentasvir has proven to perform well in patients with hepatitis C genotypes 1 to 6 without cirrhosis.

Elbasvir/grazoprevir (Zepatier) and sofosbuvir (Sovaldi) are used to treat hepatitis C around the world, but is one better than the other?

Extracorporeal shock therapy helped patients with diabetes improve their range of motion when suffering from "frozen shoulder" a study in Italy found.

Gilead Sciences is seeking approval of a single tablet, 12-week combination hepatitis C regimen for patients of all genotypes previously treated for the disease with direct-acting antivirals.

An investigational combination drug that targets all major genotypes of hepatitis C had a high success rate in a clinical trial of patients with severe chronic kidney disease, curing 98% of those who received 12 weeks of treatment.

Results from three clinical trials of an investigational drug being developed by AbbVie to treat all major genotypes of the hepatitis C virus show high cure rates at or above 95% among patients tested.

A project to wipe out hepatitis C among the Cherokee Nation to has led to successful screening of thousands of people since the effort was launched a year ago, say tribal leaders.

New hepatitis C treatments made accessible through competition and other access strategies have been given to over one million patients in as many as 13 low-and middle-income countries, according to a new report from the World Health Organization (WHO).

An interesting discovery about some Irish women exposed to the hepatitis C virus in the late 1970s has led scientists to study the possible existence of a super immune gene.

The investigational drug that AbbVie is testing in clinical trials is a pan-genotypic regimen of glecaprevir and pibrentasvir, a co-formulation dosed once a day, according to the release.

The concern most likely did not come to light during clinical trials because, according to the FDA, patients who were infected with hepatitis B were excluded from participating in HCV treatment studies.

The Penn Medicine clinical trial uses kidneys from deceased donors who were infected with the hepatitis C virus. The first person in the trial received a kidney transplant in July and then underwent treatment with a regimen of Zepatier, one of the direct acting antiviral drugs approved recently to treat the virus.

Hepatitis B and C are caused by different viruses that can start as acute infections but turn chronic in some people and eventually lead to life-threatening liver damage, according to the Centers for Disease Control and Prevention. While there are vaccines to prevent hepatitis A and B, there is no vaccine for hepatitis C.

A study of Scottish patients who had been treated and cured of hepatitis C found that the group had a higher mortality rate compared to the general population.

Beyond high cost, people with hepatitis C face several barriers to treatment, and those arise from various sources. Doctors, Medicaid, private health insurance companies, and intravenous drug use can all be obstacles, according to a university study out of Massachusetts that examined treatment approvals for two new drugs.

A study in women coinfected with hepatitis C and HIV found that use of marijuana was not associated with progression to advanced liver fibrosis.

Overall sustained virologic response, a marker for a cure, was achieved in 96% of patients with genotype 1b strain of the virus after 12 weeks of Zepatier. In patients infected with genotype 4 of the virus, 94% were cured after 12 weeks of Zepatier treatment.

Recent advances in the field of hepatitis C therapy has prompted the European Medicines Agency to update its guideline for designing clinical trials on investigational direct-acting antiviral drugs that target chronic infection of the virus.

The regulator placed a clinical hold on human trials involving a new investigational hepatitis C drug that targets microRNA following a report of jaundice by someone enrolled in a study.

Citing attorney misconduct, a California federal judge overturned a jury award decision that would have required Gilead Sciences to pay $200 million in damages to pharmaceutical giant Merck.

Hepatitis C affects a disproportionate number of American Indian and Alaskan Native people, more than any other racial or ethnic group in the country, and treatment efforts are being hampered by limited government funding, according to a recent journal article.

A committee of the European Medicines Agency has recommended approval of two new combination drugs to treat chronic hepatitis C infection, the agency announced.

A study that explored the healthcare burden of chronic infection of the hepatitis C virus found that patients with the disease were more than 3 times likely to be hospitalized than patients in a comparison group.